Effect of MiR-21 on pulmonary arterial hypertension via the TGF-β1/Smad2 signal pathway

Si, Jiyuan; Yang, Bin; Yu, Jixiang; Yu, Li; Gao, Peng

doi:10.23736/s0026-4806.19.06014-2

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Signal transduction starts with the ligand-induced oligomerization of serine/threonine receptor kinases and the phosphorylation of cytoplasmic signal transduction molecules Smad2 and Smad3( 33 ). The carboxyl terminus of Smad proteins is phosphorylated by an activated receptor, causing it to bind to the common signal transduction factor Smad4 and transporting it into the nucleus ( 34 ). Activated Smad proteins regulate various biological processes by binding to transcription factors, such as BMP, leading to the transcriptional regulation of cell states ( 35 ).…”

Section: Discussionmentioning

confidence: 99%

Psoralen accelerates osteogenic differentiation of human bone marrow mesenchymal stem cells by activating the TGF‑β/Smad3 pathway

Huang

Liao

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

Psoralen, one of the active ingredients in Psoralea corylifolia, has been previously reported to regulate the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). A previous study revealed that psoralen can regulate the expression levels of microRNA-488 and runt-related transcription factor 2 (Runx2) to promote the osteogenic differentiation of BMSCs. However, the underlying signalling pathway in this process remains to be fully elucidated. BMSCs have also been confirmed to play a key role in the occurrence and development of osteoporosis, and are expected to be potential seed cells in the treatment of osteoporosis. In order to explore the potential signalling pathways of psoralen acting on BMSCs, in the present study, human BMSCs (hBMSCs) were treated with different concentrations of psoralen (0.1, 1, 10 and 100 µmol/l) and the TGF-β receptor I (RI) inhibitor SB431542 (5 µmol/l) in vitro for 3, 7 or 14 days. Cell Counting Kit-8 and MTT assays were used to measure cell proliferation and cell viability of hBMSCs following psoralen administration. Alkaline phosphatase (ALP) activity and alizarin red S staining were used to assess the osteogenic differentiation ability of hBMSCs. Reverse transcription-quantitative PCR and western blotting were used to measure the expression of osteogenic differentiation-related genes [bone morphogenetic protein 4 (BMP4), osteopontin (OPN), Runx2 and Osterix] and proteins associated with the TGF-β/Smad3 pathway [TGF-β1, TGF-β RI, phosphorylated (p-)Smad and Smad3]. Psoralen was found to increase the proliferation and viability of hBMSCs. Although different concentrations of psoralen enhanced ALP activity and the calcified nodule content in hBMSCs, the enhancement effects were more potent at lower concentrations (0.1, 1 and 10 µmol/l). The expression of BMP4, OPN, Osterix, Runx2, TGF-β1, TGF-β RI and p-Smad3 was also promoted by psoralen at lower concentrations (0.1, 1 and 10 µmol/l). In addition, whilst SB431542 could inhibit calcium deposition and osteogenic differentiation-related gene expression in hBMSCs, psoralen effectively reversed the inhibitory effects of SB431542. In conclusion, psoralen accelerates the osteogenic differentiation of hBMSCs by activating the TGF-β/Smad3 pathway, which may be valuable for the future clinical treatment of osteoporosis.

show abstract

Section: Discussionmentioning

confidence: 99%